Real-life effectiveness and safety of dupilumab in adolescents with atopic dermatitis: a 52-week single-center retrospective study.

Abstract

Dupilumab is a monoclonal antibody that selectively targets the alpha subunit of the interleukin-4-Receptor and it is approved for the treatment of atopic dermatitis in adults, children and adolescents. Real life data on effectiveness and safety of dupilumab in adolescents are limited.In this study, 30 patients who started dupilumab between the ages of 12 and 18 were evaluated. All patients completed at least 16 weeks of therapy, with 25 reaching week 52. In our experience, the mean Eczema Area and Severity Index decreased from 23.25 ± 4.15 at baseline to 2.06 ± 1.99 at week 52.